The Melanoma Institute Australia team made a significant contribution to cancer research discussions during ESMO23, held recently in Madrid. At the Opening Ceremony Professor Georgina Long received the ESMO Women for Oncology Award 2023, and then delivered a 15-minute presentation on ‘Breaking ground in 2023’.
The European Society for Medical Oncology (ESMO) Congress is a highly influential global oncology conference, recently held in Madrid.
At the Opening Session of ESMO2023 Prof Georgina Long AO was presented with the ESMO Women for Oncology Award 2023, in recognition of her significant contribution and the inspiring role she plays in the field of oncology. As part of this award Georgina was invited to deliver an impactful 15-minute lecture on ‘Breaking ground in 2023’.
The ESMO23 program featured over 250 sessions, and Melanoma Institute Australia was well represented with Prof Georgina Long, Assoc Prof Alexander van Akkooi and Dr Ines Pires da Silva participating in oral sessions and MIA researchers presenting posters on groundbreaking research projects.
Orals
ESMO Women for Oncology Award lecture: Breaking ground in 2023. Prof Georgina Long AO.
Controversy session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy
Session Chair Georgina V Long
Special Symposium: What’s the future in melanoma therapy? Novel targets, new drugs, reinvented approaches
Ines Pires da Silva – Clinical data, NGS, (x)-omics et al.: What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors?
Multidisciplinary session – Early-stage (II/III) melanoma: Risk stratification and treatment decisions
Alexander Van Akkooi – Further development of the clinical case: A surgeon’s perspective – Do we still need surgery in the era of risk scores stratification and systemic therapy?
Mini Oral session – Melanoma and other skin tumours – Chair Georgina V Long
Invited Discussant 1083MO and 1084MO – Georgina V Long
Posters – MIA presenting:
1103P – Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Speaker: Georgina V Long
1106P – Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets).
Speaker: Ines Pires da Silva
1149P – Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment.
Speaker: Lisanne Zijlker
1165P – Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Speaker: Xinyu Bai
Posters – MIA Author, Other Institution presenting
1089P – Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Speaker: Paolo A Ascierto
1091P – Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
Speaker: Jeffrey S Weber
1095P – Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Speaker: Irene Reijers
1096P – Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma
Speaker Minke W Lucas
1099P – Long-term survival follow-up from the REDUCTOR trial: Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection
Speaker Femke H Burgers
1120P – Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Speaker Robert C Stassen
1127P – Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Speaker: James P Pham
Leave A Comment